{"id":"additional-doses-of-rituximab","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Infusion reactions"},{"rate":"20-40","effect":"Infections"},{"rate":"5-15","effect":"Cytopenias (anemia, thrombocytopenia, neutropenia)"},{"rate":"10-20","effect":"Fatigue"},{"rate":"5-10","effect":"Fever"},{"rate":"5-10","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1201576","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rituximab targets the CD20 antigen expressed on the surface of B lymphocytes. By binding to CD20, it triggers immune-mediated destruction of B cells through multiple mechanisms including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis. This B cell depletion reduces autoimmune responses and is effective in conditions driven by pathogenic B cells.","oneSentence":"Rituximab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:59:41.566Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Non-Hodgkin's lymphoma"},{"name":"Chronic lymphocytic leukemia"},{"name":"Granulomatosis with polyangiitis"},{"name":"Microscopic polyangiitis"}]},"trialDetails":[{"nctId":"NCT00428142","phase":"PHASE2","title":"Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2007-05-01","conditions":"Lymphoma","enrollment":95},{"nctId":"NCT06890884","phase":"PHASE2","title":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-11","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":594},{"nctId":"NCT07410039","phase":"PHASE4","title":"Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-02-01","conditions":"Neuromyelitis Optica Spectrum Disorder Attack","enrollment":200},{"nctId":"NCT01419561","phase":"PHASE2","title":"Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-09-08","conditions":"KSHV Inflammatory Cytokine Syndrome (KICS), KSHV, HHV-8","enrollment":140},{"nctId":"NCT07029737","phase":"PHASE2","title":"A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-09-05","conditions":"Mantle-cell Lymphoma","enrollment":55},{"nctId":"NCT03789240","phase":"PHASE2","title":"Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-22","conditions":"Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL","enrollment":33},{"nctId":"NCT01473628","phase":"PHASE1, PHASE2","title":"Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-05-20","conditions":"Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1 Follicular Lymphoma","enrollment":81},{"nctId":"NCT03286556","phase":"PHASE2","title":"Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2018-09-04","conditions":"Idiopathic Pulmonary Fibrosis, Acute Fatal Form","enrollment":82},{"nctId":"NCT05898308","phase":"PHASE4","title":"Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2024-12-04","conditions":"Pemphigus, Dermatologic Disease","enrollment":133},{"nctId":"NCT05551936","phase":"PHASE1, PHASE2","title":"A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vaishalee Kenkre","startDate":"2023-01-26","conditions":"Follicular Lymphoma","enrollment":42},{"nctId":"NCT02158091","phase":"PHASE1, PHASE2","title":"A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-06-27","conditions":"Chronic Lymphocytic Leukemia","enrollment":32},{"nctId":"NCT07398638","phase":"PHASE1, PHASE2","title":"Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-28","conditions":"Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":122},{"nctId":"NCT01516580","phase":"PHASE3","title":"Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2011-12","conditions":"B-cell Non Hodgkin Lymphoma, Mature B-cell Leukemia Burkitt-type","enrollment":482},{"nctId":"NCT05660369","phase":"PHASE1","title":"CARv3-TEAM-E T Cells in Glioblastoma","status":"RECRUITING","sponsor":"Marcela V. Maus, M.D.,Ph.D.","startDate":"2023-03-22","conditions":"Glioblastoma, Malignant Glioma, Recurrent Glioblastoma","enrollment":21},{"nctId":"NCT02315326","phase":"PHASE1, PHASE2","title":"Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-12-08","conditions":"Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)","enrollment":93},{"nctId":"NCT04669171","phase":"PHASE1, PHASE2","title":"A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Enterome","startDate":"2021-07-05","conditions":"Follicular Lymphoma, Marginal Zone Lymphoma","enrollment":80},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT06342544","phase":"PHASE3","title":"Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.","status":"RECRUITING","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2025-04-29","conditions":"Ocular Myasthenia Gravis","enrollment":128},{"nctId":"NCT05735834","phase":"PHASE3","title":"Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2024-05-21","conditions":"Splenic Marginal Zone Lymphoma","enrollment":122},{"nctId":"NCT01350882","phase":"PHASE3","title":"Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2008-10","conditions":"Humoral Rejection in Kidney Transplantation","enrollment":40},{"nctId":"NCT06006117","phase":"PHASE3","title":"Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2023-09-05","conditions":"Marginal Zone Lymphoma","enrollment":260},{"nctId":"NCT03952637","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis","status":"RECRUITING","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"2019-08-19","conditions":"Lysosomal Diseases, Gangliosidosis, GM1","enrollment":54},{"nctId":"NCT07080125","phase":"","title":"A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2025-06-17","conditions":"Interstitial Lung Diseases, Systemic Sclerosis Associated Interstitial Lung Disease","enrollment":2000},{"nctId":"NCT04010968","phase":"PHASE2","title":"Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"2019-09-27","conditions":"Intermediate Risk Chronic Lymphocytic Leukemia, Fit Patients, Risk-Adapted and MRD-Driven Strategy","enrollment":120},{"nctId":"NCT05270057","phase":"PHASE1","title":"Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-01-26","conditions":"B-cell Lymphoma, Burkitt Lymphoma","enrollment":11},{"nctId":"NCT07039877","phase":"PHASE2","title":"Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients","status":"RECRUITING","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2025-01-02","conditions":"Acute Lymphobkastic Leukemia, Acute Lymphoblastic Leukaemia Recurrent, Philadelphia Chromosome Negative ALL","enrollment":12},{"nctId":"NCT05058404","phase":"PHASE3","title":"Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2021-12-01","conditions":"Follicular Lymphoma","enrollment":605},{"nctId":"NCT06977711","phase":"PHASE1","title":"Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2025-06-20","conditions":"Diffuse Large B-cell Lymphoma","enrollment":10},{"nctId":"NCT04400994","phase":"PHASE2","title":"IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2020-06-20","conditions":"Pemphigus","enrollment":20},{"nctId":"NCT01776840","phase":"PHASE3","title":"A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-05-16","conditions":"Mantle Cell Lymphoma","enrollment":523},{"nctId":"NCT05253495","phase":"PHASE2","title":"Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2022-02-01","conditions":"Non-hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":80},{"nctId":"NCT05025423","phase":"PHASE2","title":"Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2022-06-21","conditions":"Mantle Cell Lymphoma","enrollment":7},{"nctId":"NCT01059786","phase":"PHASE2","title":"Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-07-01","conditions":"Hairy Cell Leukemia","enrollment":69},{"nctId":"NCT03995147","phase":"PHASE2","title":"Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2019-08-29","conditions":"B Cell Lymphoma, Lymphoma, Lymphoma, B-Cell","enrollment":51},{"nctId":"NCT06611696","phase":"PHASE4","title":"Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis","status":"RECRUITING","sponsor":"Chiba University","startDate":"2024-11-15","conditions":"ANCA Associated Vasculitis (AAV)","enrollment":160},{"nctId":"NCT05862766","phase":"EARLY_PHASE1","title":"Isatuximab in Lung Transplant Recipients","status":"WITHDRAWN","sponsor":"NYU Langone Health","startDate":"2024-12-01","conditions":"Antibody-mediated Rejection, Allosensitization","enrollment":""},{"nctId":"NCT01085617","phase":"","title":"Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"University College, London","startDate":"2010-12","conditions":"Leukemia, Mucositis, Oral Complications","enrollment":""},{"nctId":"NCT03206671","phase":"PHASE3","title":"Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital Muenster","startDate":"2017-08-03","conditions":"Mature B-cell Non-Hodgkin Lymphoma","enrollment":650},{"nctId":"NCT04525729","phase":"PHASE4","title":"Rituximab and RASi in Patients with IgAN","status":"COMPLETED","sponsor":"Nan Chen,MD","startDate":"2020-07-01","conditions":"IgA Nephropathy","enrollment":116},{"nctId":"NCT06871007","phase":"PHASE1, PHASE2","title":"Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma","status":"ENROLLING_BY_INVITATION","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2024-09-01","conditions":"Primary Mediastinal (Thymic) Large B-cell Lymphoma, Children, Nivolumab","enrollment":22},{"nctId":"NCT06830421","phase":"PHASE3","title":"Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients","status":"RECRUITING","sponsor":"University Hospital Freiburg","startDate":"2023-08-09","conditions":"Primary Central Nervous System Lymphoma","enrollment":340},{"nctId":"NCT05144009","phase":"PHASE2","title":"A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)","status":"TERMINATED","sponsor":"ADC Therapeutics S.A.","startDate":"2022-06-21","conditions":"Diffuse Large B-cell Lymphoma","enrollment":41},{"nctId":"NCT03366272","phase":"PHASE2, PHASE3","title":"Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients","status":"COMPLETED","sponsor":"Universität des Saarlandes","startDate":"2017-12-05","conditions":"Lymphoma, Non-Hodgkin","enrollment":348},{"nctId":"NCT05850546","phase":"PHASE3","title":"Rituximab in the First Episode of Paediatric Nephrotic Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2025-03-01","conditions":"Steroid-Sensitive Nephrotic Syndrome","enrollment":138},{"nctId":"NCT04106830","phase":"","title":"Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2019-01-01","conditions":"NMO Spectrum Disorder, MRI, Multiple Sclerosis","enrollment":1000},{"nctId":"NCT06680349","phase":"PHASE4","title":"Two Anti-CD20 Regimens for Fibrillary Glomerulonephritis","status":"COMPLETED","sponsor":"University of Turin, Italy","startDate":"2022-12-01","conditions":"Fibrillary Glomerulonephritis","enrollment":21},{"nctId":"NCT01199575","phase":"PHASE2","title":"Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2010-08","conditions":"Chronic Lymphocytic Leukemia, CLL","enrollment":30},{"nctId":"NCT05696613","phase":"PHASE3","title":"A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy","status":"RECRUITING","sponsor":"Cerium Pharmaceuticals, Inc.","startDate":"2023-03-13","conditions":"Primary Membranous Nephropathy","enrollment":148},{"nctId":"NCT06336395","phase":"PHASE2","title":"Ma-Spore ALL 2020 Study","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2020-03-04","conditions":"B Lymphoblastic Leukemia","enrollment":500},{"nctId":"NCT04762160","phase":"PHASE2","title":"SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma","status":"TERMINATED","sponsor":"Epizyme, Inc.","startDate":"2020-12-15","conditions":"Follicular Lymphoma","enrollment":5},{"nctId":"NCT04002401","phase":"PHASE2","title":"Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2019-11-05","conditions":"Refractory Large B-cell Lymphoma","enrollment":27},{"nctId":"NCT04656431","phase":"PHASE1","title":"Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma","status":"UNKNOWN","sponsor":"James Rubenstein","startDate":"2021-06-29","conditions":"Primary CNS Lymphoma","enrollment":25},{"nctId":"NCT06245707","phase":"NA","title":"the Effects of Different Treatment Schemes on Cognitive Function of Patients With Idiopathic Membranous Nephropathy","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2023-10-01","conditions":"Mild Cognitive Impairment, Idiopathic Membranous Nephropathy","enrollment":2},{"nctId":"NCT02658968","phase":"PHASE1","title":"Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)","status":"COMPLETED","sponsor":"Nordic Nanovector","startDate":"2017-03-02","conditions":"Relapsed, Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":18},{"nctId":"NCT04263584","phase":"PHASE2","title":"Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL","status":"UNKNOWN","sponsor":"University Hospital Muenster","startDate":"2020-06-19","conditions":"Diffuse Large B Cell Lymphoma","enrollment":62},{"nctId":"NCT05577364","phase":"PHASE1, PHASE2","title":"Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-11-01","conditions":"EBV-Positive Diffuse Large B-Cell Lymphoma, Nos","enrollment":54},{"nctId":"NCT03689894","phase":"PHASE1, PHASE2","title":"Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT","status":"TERMINATED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2019-04-11","conditions":"Chronic Graft-versus-host-disease","enrollment":2},{"nctId":"NCT03096782","phase":"PHASE2","title":"Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-10-13","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia","enrollment":6},{"nctId":"NCT00080886","phase":"PHASE2","title":"Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2002-05-08","conditions":"Lymphoma","enrollment":68},{"nctId":"NCT04224571","phase":"PHASE2","title":"CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2018-09-14","conditions":"Acute Lymphoblastic Leukemia, in Relapse","enrollment":208},{"nctId":"NCT00101101","phase":"PHASE2","title":"Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2004-07","conditions":"Lymphoma","enrollment":43},{"nctId":"NCT03121677","phase":"PHASE1","title":"Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2018-10-16","conditions":"Follicular Lymphoma","enrollment":4},{"nctId":"NCT00335140","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma","status":"TERMINATED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2007-08-23","conditions":"Lymphoma","enrollment":26},{"nctId":"NCT01682616","phase":"PHASE1","title":"A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma","status":"COMPLETED","sponsor":"AbbVie","startDate":"2012-07-25","conditions":"Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia","enrollment":49},{"nctId":"NCT05824390","phase":"PHASE4","title":"A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy","status":"UNKNOWN","sponsor":"XIEJINGYUAN","startDate":"2020-06-20","conditions":"IgA Nephropathy","enrollment":116},{"nctId":"NCT03688451","phase":"PHASE2","title":"Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Tahir Latif","startDate":"2018-10-29","conditions":"Non Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT03064867","phase":"PHASE1, PHASE2","title":"Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Molly Gallogly","startDate":"2017-06-26","conditions":"Diffuse Large B-cell-lymphoma","enrollment":65},{"nctId":"NCT04880577","phase":"PHASE2","title":"Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2022-09-15","conditions":"Multiple Sclerosis, Relapsing-Remitting, Fatigue","enrollment":""},{"nctId":"NCT01319981","phase":"PHASE2","title":"Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-03-05","conditions":"Leukemia","enrollment":31},{"nctId":"NCT04507477","phase":"PHASE1, PHASE2","title":"Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2020-07-07","conditions":"Epstein-Barr Virus Infections, Post-transplant Lymphoproliferative Disorder","enrollment":10},{"nctId":"NCT04138875","phase":"PHASE2","title":"A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)","status":"WITHDRAWN","sponsor":"Yale University","startDate":"2022-01","conditions":"PTLD, Lymphoid Tumor, Hematopoietic/Lymphoid Cancer","enrollment":""},{"nctId":"NCT01813227","phase":"PHASE2","title":"A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531","status":"COMPLETED","sponsor":"Hackensack Meridian Health","startDate":"2013-04","conditions":"Waldenstrom Macroglobulinemia","enrollment":7},{"nctId":"NCT04155840","phase":"PHASE2","title":"Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"TERMINATED","sponsor":"University of Washington","startDate":"2020-01-31","conditions":"Lymphoid Leukemia, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia","enrollment":1},{"nctId":"NCT05049473","phase":"PHASE2","title":"Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.","status":"UNKNOWN","sponsor":"PETHEMA Foundation","startDate":"2014-01","conditions":"Mature B-Cell Leukemia Burkitt Type, Burkitt Lymphoma (BL), Unclassifiable Lymphoma Between DCBL and BL","enrollment":100},{"nctId":"NCT00324467","phase":"PHASE2","title":"Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment","status":"UNKNOWN","sponsor":"British Columbia Cancer Agency","startDate":"2006-08","conditions":"Lymphoma, Non-Hodgkin, Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma","enrollment":150},{"nctId":"NCT01434472","phase":"PHASE2","title":"High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2011-11-16","conditions":"Post-Transplant Lymphoproliferative Disorder, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT01644253","phase":"PHASE1","title":"Phase 1b Safety and Efficacy Study of TRU-016","status":"TERMINATED","sponsor":"Aptevo Therapeutics","startDate":"2012-09","conditions":"Chronic Lymphocytic Leukemia, Peripheral T-cell Lymphoma","enrollment":87},{"nctId":"NCT00317096","phase":"PHASE3","title":"FCM Versus R-FCM Followed by R-Maintenance or Observation Only","status":"UNKNOWN","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"1998-11","conditions":"Lymphoma, Follicular, Lymphoma, Low-Grade, Lymphoma, Intermediate-Grade","enrollment":319},{"nctId":"NCT01460602","phase":"PHASE1, PHASE2","title":"Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma","status":"WITHDRAWN","sponsor":"Louisiana State University Health Sciences Center Shreveport","startDate":"2010-05","conditions":"Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma","enrollment":""},{"nctId":"NCT00598169","phase":"PHASE1","title":"Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2007-11","conditions":"Lymphoma","enrollment":23},{"nctId":"NCT00267865","phase":"PHASE2","title":"Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-09-14","conditions":"AIDS-Related-Primary Central Nervous System Lymphoma","enrollment":12},{"nctId":"NCT04274257","phase":"PHASE2, PHASE3","title":"A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis","status":"COMPLETED","sponsor":"Tokyo University","startDate":"2017-12-04","conditions":"Scleroderma, Systemic, Skin Sclerosis, Lung Fibrosis","enrollment":56},{"nctId":"NCT00691652","phase":"PHASE1, PHASE2","title":"Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2008-05","conditions":"Lymphoma","enrollment":2},{"nctId":"NCT02268045","phase":"PHASE3","title":"Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"mAbxience Research S.L.","startDate":"2013-05","conditions":"Diffuse Large B-cell Lymphoma","enrollment":272},{"nctId":"NCT00949988","phase":"PHASE1, PHASE2","title":"A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2009-05","conditions":"Chronic Lymphocytic Leukemia","enrollment":3},{"nctId":"NCT01180036","phase":"PHASE2, PHASE3","title":"MEmbranous Nephropathy Trial Of Rituximab","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2011-11","conditions":"Idiopathic Membranous Nephropathy","enrollment":130},{"nctId":"NCT01287741","phase":"PHASE3","title":"A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2011-07-26","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1418},{"nctId":"NCT00134082","phase":"PHASE1, PHASE2","title":"Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2005-11","conditions":"Lymphoma","enrollment":31},{"nctId":"NCT00774202","phase":"PHASE2, PHASE3","title":"Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2003-11","conditions":"Immune Thrombocytopenic Purpura","enrollment":17},{"nctId":"NCT01318915","phase":"EARLY_PHASE1","title":"Research Study of ATG and Rituximab in Renal Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-07-25","conditions":"Renal Transplant Recipients","enrollment":10},{"nctId":"NCT01178216","phase":"PHASE1, PHASE2","title":"Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation","status":"COMPLETED","sponsor":"Stanley Jordan, MD","startDate":"2013-09","conditions":"End Stage Renal Disease","enrollment":41},{"nctId":"NCT01900496","phase":"PHASE1","title":"Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2014-06","conditions":"Lymphoma","enrollment":6},{"nctId":"NCT03298698","phase":"PHASE3","title":"Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2018-08-22","conditions":"Idiopathic Nephrotic Syndrome, Minimal Change Disease, Focal Segmental Glomerulosclerosis","enrollment":40},{"nctId":"NCT00392834","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2006-09","conditions":"Lymphoma","enrollment":34},{"nctId":"NCT01596127","phase":"PHASE1, PHASE2","title":"Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-01-24","conditions":"Leukemia, Lymphoid Malignancies, Metastatic Malignant Neoplasm to the Leptomeninges","enrollment":4},{"nctId":"NCT01200589","phase":"PHASE3","title":"Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-10-11","conditions":"Non-Hodgkin's Lymphoma","enrollment":438},{"nctId":"NCT00669877","phase":"PHASE2","title":"Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2002-08","conditions":"Burkitt's Lymphoma, Burkitt'S-like Lymphoma","enrollment":56},{"nctId":"NCT02626845","phase":"PHASE4","title":"Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis","status":"TERMINATED","sponsor":"Hospital for Special Surgery, New York","startDate":"2015-12","conditions":"Granulomatosis With Polyangiitis (Wegener's Granulomatosis)","enrollment":3},{"nctId":"NCT01373229","phase":"PHASE1","title":"Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)","status":"COMPLETED","sponsor":"David Rizzieri, MD","startDate":"2012-01","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":21},{"nctId":"NCT00554164","phase":"PHASE3","title":"Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas","status":"COMPLETED","sponsor":"University Hospital, Essen","startDate":"2007-11","conditions":"Lymphoma, High-grade","enrollment":1073}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Additional doses of Rituximab","genericName":"Additional doses of Rituximab","companyName":"University Hospital Muenster","companyId":"university-hospital-muenster","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rituximab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Used for Rheumatoid arthritis, Non-Hodgkin's lymphoma, Chronic lymphocytic leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}